Insmed Incorporated (NASDAQ:INSM) is among the Best Healthcare Stocks.
On June 15, Mizuho lowered its price target on Insmed Incorporated (NASDAQ:INSM) to $192 from $202. It maintained an Outperform rating on the shares. The firm stated the recent selloff created a buying opportunity even though shares have fallen 29% since the company's first-quarter report.
Mizuho found the sharp move in investor sentiment "shocking" and expressed confidence in both Insmed and BRINSUPRI.
Separately, on June 23, Insmed Incorporated (NASDAQ:INSM) announced that it appointed Samuele Butera as Senior Vice President and General Manager, Global Respiratory, effective immediately. He will lead the firm's Respiratory Therapeutic Area, report to Chair and CEO Will Lewis, and join the executive committee.
Lewis said Butera's commercial leadership experience would support the launch of BRINSUPRI, the potential label expansion of ARIKAYCE, and the development of the TPIP program.
On June 15, Mizuho lowered its price target on Insmed Incorporated (NASDAQ:INSM) to $192 from $202. It maintained an Outperform rating on the shares. The firm stated the recent selloff created a buying opportunity even though shares have fallen 29% since the company's first-quarter report.
Mizuho found the sharp move in investor sentiment "shocking" and expressed confidence in both Insmed and BRINSUPRI.
Separately, on June 23, Insmed Incorporated (NASDAQ:INSM) announced that it appointed Samuele Butera as Senior Vice President and General Manager, Global Respiratory, effective immediately. He will lead the firm's Respiratory Therapeutic Area, report to Chair and CEO Will Lewis, and join the executive committee.
Lewis said Butera's commercial leadership experience would support the launch of BRINSUPRI, the potential label expansion of ARIKAYCE, and the development of the TPIP program.
2 months ago
